Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mona Fouad"'
Autor:
Omar Abdel-Rahman, Mona Fouad
Publikováno v:
Expert Review of Anticancer Therapy. 15:465-475
We performed a meta-analysis of diarrhea and stomatitis associated with erlotinib use in patients with advanced non-small cell lung cancer. Eligible studies included randomized trials of patients with non-small cell lung cancer on erlotinib describin
Autor:
Omar Abdel-Rahman, Mona Fouad
Publikováno v:
Expert Review of Anticancer Therapy. 15:477-486
We performed a meta-analysis of fatigue associated with the use of everolimus, temsirolimus or ridaforolimus in patients with solid tumors. Eligible studies included randomized trials of patients with solid tumors on everolimus, temsirolimus or ridaf
Autor:
Omar Abdel-Rahman, Mona Fouad
Publikováno v:
Expert Review of Anticancer Therapy. 14:751-760
We performed a systematic review and meta-analysis of mucocutaneous toxicities associated with sorafenib, an oral multi tyrosine kinase inhibitor. Eligible studies included randomized Phase II and III trials of patients with solid tumors on sorafenib
Autor:
Omar Abdel-Rahman, Mona Fouad
Publikováno v:
Future oncology (London, England). 11(1)
ABSTRACT Background: We performed a systematic review and meta-analysis of fatigue, hepatic and metabolic toxicities associated with everolimus intake in patients with solid tumors. Methods: Eligible studies included randomized trials of patients wit
Autor:
Omar Abdel-Rahman, Mona Fouad
Publikováno v:
Expert review of anticancer therapy. 14(9)
We performed a systematic review and meta-analysis of thyroid function abnormalities associated with seven vascular endothelial growth factor receptor (VEGFR) targeted tyrosine kinase inhibitors (sorafenib, sunitinib, axitinib, cediranib, pazopanib,
Autor:
Mona Fouad, Omar Abdel-Rahman
Publikováno v:
Critical reviews in oncology/hematology. 92(3)
We performed a systematic review and comparative meta-analysis of cardiovascular toxicities associated with sunitinib, axitinib, cediranib or regorafenib; oral multi tyrosine kinase inhibitors.Eligible studies included randomized phase II and III tri